«The compounds identified in this study, when administered orally, both reduced the inflammation that is a hallmark of multiple sclerosis and protected against the nerve cell damage
seen in mouse models of the disease,» said Jeffery Haines, PhD, a post-doctoral fellow at Mount Sinai and the study's lead author.
Not exact matches
«It would be interesting to
model some
of these
diseases in mice and
see if supplementing NMN provides any benefit to their behavior or memory.»
The scientists then tested three new mTOR inhibitors currently under development (pp242, AZD8055 and INK128)
in combination with the chemotherapies AraC, Etoposide and Cisplatin to
see how they affected laboratory lines
of leukemia cells and
mouse models of the
disease.
Taking this one step further, the researchers performed the same experiments
in a
mouse model of Alzheimer's
disease to
see if these astrocytic adenosine receptors were also involved
in memory loss associated with the
disease.
Although genetically modified
mice have been used widely to
model neurodegenerative
diseases, they lack the typical neurodegeneration or overt neuronal loss
seen in human brains, says corresponding author Xiao - Jiang Li, MD, PhD, distinguished professor
of human genetics at Emory University School
of Medicine.
To
see whether blocking CD47 could reverse plaque buildup, the group tested the experimental anticancer antibody drug
in several different
mouse models of cardiovascular
disease.